

# INFECTIOUS DISEASES II PANEL

---

## EDITORIAL BOARD LIAISON

Marisel Segarra-Newnham, Pharm.D.,  
MPH, FCCP, BCPS  
*Clinical Pharmacy Specialist, Infectious Diseases*  
Pharmacy Service  
Veterans Affairs Medical Center  
West Palm Beach, Florida  
*Clinical Assistant Professor of Pharmacy Practice*  
University of Florida College of Pharmacy  
Gainesville, Florida

## ANTIMICROBIAL STEWARDSHIP

### Authors

Marc H. Scheetz, Pharm.D., BCPS  
(AQ Infectious Diseases)  
*Assistant Professor*  
Department of Pharmacy Practice  
Midwestern University Chicago College of Pharmacy  
Downers Grove, Illinois  
*Infectious Diseases Pharmacist*  
Department of Pharmacy  
Northwestern Memorial Hospital  
Chicago, Illinois

Michael Postelnick, BSPHarm, BCPS  
(AQ Infectious Diseases)  
*Senior Infectious Diseases Pharmacist*  
*Manager, Research and Education*  
Department of Pharmacy  
Northwestern Memorial Hospital  
Chicago, Illinois

### Reviewers

Anne L. Hume, Pharm.D., FCCP, BCPS  
*Professor of Pharmacy*  
Department of Pharmacy Practice  
University of Rhode Island  
Kingston, Rhode Island  
*Adjunct Professor of Family Medicine*  
Alpert School of Medicine at Brown University  
Providence, Rhode Island

Craig A. Martin, Pharm.D., BCPS  
(AQ Infectious Diseases)  
*Pharmacist Specialist – Infectious Diseases*  
Department of Pharmacy Services  
UK Healthcare

### Associate Professor

Department of Pharmacy Practice and Science  
Department of Internal Medicine  
University of Kentucky College of Pharmacy  
Lexington, Kentucky

## OPHTHALMIC AND OTIC INFECTION

### Author

Ryan P. Moenster, Pharm.D., BCPS  
(AQ Infectious Diseases)  
*Clinical Pharmacist – Infectious Diseases*  
Department of Pharmacy  
St. Louis VA Medical Center – John Cochran Division  
*Assistant Professor of Pharmacy Practice*  
Department of Pharmacy Practice  
St. Louis College of Pharmacy  
St. Louis, Missouri

### Reviewers

Brian A. Hemstreet, Pharm.D., BCPS  
*Associate Professor*  
*Director, Pharmaceutical Care Learning Center*  
Department of Clinical Pharmacy  
University of Colorado School of Pharmacy  
Aurora, Colorado

David J. Ritchie, Pharm.D., FCCP, BCPS  
(AQ Infectious Diseases)  
*Clinical Pharmacist, Infectious Disease*  
Barnes-Jewish Hospital  
*Professor of Pharmacy Practice*  
St. Louis College of Pharmacy  
St. Louis, Missouri

## CENTRAL NERVOUS SYSTEM INFECTIONS

### Author

Lisa M. Avery, Pharm.D., BCPS  
*Associate Professor*  
Department of Pharmacy Practice  
Wegman's School of Pharmacy  
St. John Fisher College  
Rochester, New York  
*Infectious Disease Clinical Pharmacy Specialist*  
St. Joseph's Hospital Health Center  
Syracuse, New York

## Reviewers

Jarrett R. Amsden, Pharm.D., BCPS  
*Assistant Professor*  
Department of Pharmacy Practice  
Butler University College of Pharmacy  
and Health Sciences  
*Infectious Diseases Clinical Pharmacist*  
Department of Clinical Pharmacy  
Community Health Network  
Indianapolis, Indiana

Marianne McCollum, Ph.D., BSPHarm, BCPS  
*Interim Dean*  
School of Pharmacy  
Rueckert-Hartman College for Health Professions  
Regis University  
Denver, Colorado

## METHICILLIN-RESISTANT *S. AUREUS*

### Authors

Vanthida Huang, Pharm.D.  
*Associate Professor*  
Department of Pharmacy Practice  
Mercer University College of Pharmacy  
and Health Sciences  
Atlanta, Georgia  
*Infectious Disease Clinical Pharmacy Specialist*  
Department of Pharmacy  
Atlanta Medical Center  
Atlanta, Georgia

Phillip Owen, Pharm.D., BCPS  
*Clinical Assistant Professor*  
Department of Pharmacy Practice  
Mercer University College of Pharmacy  
and Health Sciences  
*Critical Care Clinical Pharmacy Specialist*  
Department of Pharmacy  
Atlanta Medical Center  
Atlanta, Georgia

## Reviewers

Katherine Hammond Chessman,  
Pharm.D., FCCP, BCPS, BCNSP  
*Professor*  
Department of Clinical Pharmacy  
and Outcome Sciences  
*Pediatric Pharmacy Practice Residency Program Director*  
South Carolina College of Pharmacy  
Medical University of South Carolina Campus  
*Clinical Pharmacy Specialist*  
Pediatrics/Pediatric Surgery  
MUSC Children's Hospital  
Charleston, South Carolina

Jennifer Le, Pharm.D., FCCP, BCPS  
(AQ Infectious Diseases)  
*Associate Professor of Clinical Pharmacy*  
Department of Clinical Pharmacy  
University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences  
La Jolla, California

*The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 9, Infectious Diseases II chapters:*

H. Gwen Bartlett, Pharm.D., BCPS  
*Clinical Pharmacist III*  
Department of Pharmacy  
St. Francis Health Center  
Topeka, Kansas

Nicola G. Dahl, Pharm.D.  
*Medical Writer*  
Kanab, Utah

Julia Elenbaas, Pharm.D.  
Anthem, Arizona

Mary Lee, Pharm.D., FCCP, BCPS  
*Vice President and Chief Academic Officer*  
Pharmacy and Health Sciences Education  
Midwestern University  
*Professor of Pharmacy Practice*  
Midwestern University  
Chicago College of Pharmacy  
Downers Grove, Illinois

# DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

---

*Consultancies:* P. Brandon Bookstaver (Johnson & Johnson [Ortho-McNeil]); Patrick G. Clay (GlaxoSmithKline [ViiV Healthcare], U.S. Food and Drug Administration, Koronis Pharmaceuticals); Joseph T. DiPiro (American Association of Colleges of Pharmacy, U.S. Food and Drug Administration, AACP); Shannon W. Finks (Novartis Pharmaceuticals); Brian A. Hemstreet (Conexus Health); Vanthida Huang (Astellas Pharma [Theravance Inc.], Ortho-McNeil); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Amy Pakyz (Ortho-McNeil), Jean A. Patel (University Health System Consortium); Michael Postelnick (Hospira); Michelle Richardson (Amgen, QualityMetric); David J. Ritchie (Pfizer, Astellas Pharma); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, Annals of Pharmacotherapy); Jeffrey T. Sherer (Sturge-Weber Foundation); Douglas Slain (Wyeth)

*Stock Ownership:* Lisa M. Avery (Merck); Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Joseph T. DiPiro (Bristol Myers Squibb, Pfizer); Lisa C. Hutchison (Cardinal Health)

*Royalties:* Joseph T. DiPiro (McGraw-Hill, ASHP); Lisa C. Hutchison (ASHP)

*Grants:* Jarrett R. Amsden (Astellas Pharma); P. Brandon Bookstaver (Cubist Pharmaceuticals, Astellas Pharma, Merck & Co); Kevin W. Garey (Merck); Jennifer Hagerman (Gilead); Brian A. Hemstreet (AstraZeneca); Anne L.

Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Michael B. Kays (Ortho-McNeil); Michael E. Klepser (Gilead); Jennifer Le (NIH/NIAID, Cubist, Memorialcare Foundation); Craig A. Martin (Pfizer); Amy Pakyz (Cubist, ViroPharma, AHRQ); Charles A. Peloquin (Jacobus Pharmaceuticals); Marc H. Scheetz (Cubist, TheraDoc, Inc., BioCryst Pharmaceuticals)

*Honoraria:* Lisa M. Avery (Astellas Pharma); Elias B. Chahine (Optimer Pharmaceuticals, Inc.); Clarence Chant (Hospira Canada and Drug Intelligence Inc.); Vanthida Huang (Forest, Cubist); Lisa C. Hutchison (American College of Clinical Pharmacy, American Society of Health-System Pharmacists); Michael B. Kays (Astellas Pharma, Merck); Michael E. Klepser (Cubist), Jennifer Le (Pfizer); Jean A. Patel (Northwestern Feinberg School of Medicine Physician Assistant Program, Scottsdale Institute) Michelle Richardson (Amgen); David J. Ritchie (Astellas Pharma, Cubist)

*Other:*

*Nothing to Disclose:* David T. Bearden; Pamela Belperio; Adam B. Jackson; Emilie Karpiuk; Marianne McCollum; Ryan Moenster; Rocsanna Namdar; Phillip S. Owen; Jason J. Schafer; Jamie S. Winner; Nancy Yunker

**ROLE OF ACCP:** ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at [www.bpsweb.org/recertification/general.cfm](http://www.bpsweb.org/recertification/general.cfm).

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties  
2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591  
[www.bpsweb.org](http://www.bpsweb.org)